Novo Nordisk Stock Crashes 20% After Slashing 2025 Sales Forecast Amid Demand Slump
Novo Nordisk stock crashed 20% after slashing 2025 sales growth forecasts due to weak demand for Wegovy and Ozempic in the U.S. and slow international rollout, pushing shares to a 57% year-to-date decline.